Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piperazine is an anthelmintic drug primarily used to treat infections caused by common roundworms (ascariasis) and pinworms (enterobiasis). It works by acting as a gamma-aminobutyric acid (GABA) receptor agonist on the muscle membrane of susceptible worms, causing hyperpolarization of nerve endings and resulting in flaccid paralysis. The paralyzed worms are then expelled from the body through normal intestinal peristalsis. Piperazine is available only by prescription and has been in clinical use since 1953 for its antiparasitic properties[1][2][3]. It is not typically used for other indications but serves as a chemical scaffold in various pharmaceutical compounds[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piperazine.